Pharmacologic conversion and suppression of experimental canine atrial flutter: differing effects of d-sotalol, quinidine, and lidocaine and significance of changes in refractoriness and conduction
- PMID: 3708774
- DOI: 10.1161/01.cir.74.1.197
Pharmacologic conversion and suppression of experimental canine atrial flutter: differing effects of d-sotalol, quinidine, and lidocaine and significance of changes in refractoriness and conduction
Abstract
The electrophysiologic determinants of conversion and the prevention of atrial flutter are poorly defined. This issue was therefore investigated by evaluating the effects of the new class III antiarrhythmic drug d-sotalol and the class I antiarrhythmic drugs quinidine and lidocaine. Atrial flutter was reproducibly induced in the open-chest anesthetized dog with intercaval crush and rapid atrial pacing. In this preparation, intravenous d-sotalol restored sinus rhythm in 14 of 15 (93%) dogs, whereas quinidine converted nine of 15 (60%) and lidocaine two of 10 (20%). d-Sotalol prevented reinduction in eight (53%), whereas quinidine was effective in four (27%) and lidocaine in none (0%). In the atria, d-sotalol induced significant increases in effective refractory period (+32%; p less than .01), functional refractory period (+30%; p less than .01), conduction time at an atrial paced cycle length of 150 msec (+9%; p less than .05), and atrial flutter cycle length (+8%; p less than .01). Quinidine increased effective refractory period (+40%; p less than .01), functional refractory period (+27%; p less than .01), conduction time at sinus cycle length (+13%; p less than .01), conduction time at an atrial paced cycle length of 150 msec (+18%; p less than .01), and atrial flutter cycle length (+31%; p less than .01). Lidocaine decreased functional refractory period (-6%; p less than .05) while lengthening the atrial flutter cycle length (+13%; p less than .05).(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Effects of N-acetylprocainamide and recainam in the pharmacologic conversion and suppression of experimental canine atrial flutter: significance of changes in refractoriness and conduction.J Cardiovasc Pharmacol. 1988 May;11(5):573-80. doi: 10.1097/00005344-198805000-00010. J Cardiovasc Pharmacol. 1988. PMID: 2455844
-
Effects of antiarrhythmic drugs on canine atrial flutter due to reentry: role of prolongation of refractory period and depression of conduction to excitable gap.J Am Coll Cardiol. 1991 Oct;18(4):1098-104. doi: 10.1016/0735-1097(91)90773-3. J Am Coll Cardiol. 1991. PMID: 1910060
-
Electrophysiologic effects of the new class III antiarrhythmic drug dofetilide compared to the class IA antiarrhythmic drug quinidine in experimental canine atrial flutter: role of dispersion of refractoriness in antiarrhythmic efficacy.J Cardiovasc Electrophysiol. 1996 Sep;7(9):809-27. doi: 10.1111/j.1540-8167.1996.tb00594.x. J Cardiovasc Electrophysiol. 1996. PMID: 8884510
-
Dofetilide versus quinidine for atrial flutter: viva la difference!?J Cardiovasc Electrophysiol. 1996 Sep;7(9):828-32. doi: 10.1111/j.1540-8167.1996.tb00595.x. J Cardiovasc Electrophysiol. 1996. PMID: 8884511 Review.
-
Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.Am J Cardiol. 2003 Mar 20;91(6A):15D-26D. doi: 10.1016/s0002-9149(02)03375-1. Am J Cardiol. 2003. PMID: 12670638 Review.
Cited by
-
Oral N-acetylprocainamide compared to quinidine plus digoxin in the chronic suppression of atrial flutter in humans.Cardiovasc Drugs Ther. 1989 Apr;3(2):191-8. doi: 10.1007/BF01883864. Cardiovasc Drugs Ther. 1989. PMID: 2484856 Clinical Trial.
-
Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias.Drugs. 1993 Oct;46(4):678-719. doi: 10.2165/00003495-199346040-00007. Drugs. 1993. PMID: 7506652 Review.
-
Sotalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.Drugs. 1987 Sep;34(3):311-49. doi: 10.2165/00003495-198734030-00002. Drugs. 1987. PMID: 3315621 Review.
-
Interaction of class III antiarrhythmic drugs with muscarinic M2 and M3 receptors: radioligand binding and functional studies.Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):73-9. doi: 10.1007/BF00168918. Naunyn Schmiedebergs Arch Pharmacol. 1995. PMID: 8750919
-
Progress and prospects for optimum antiarrhythmic drug design.Cardiovasc Drugs Ther. 1987 Aug;1(2):117-23. doi: 10.1007/BF02125464. Cardiovasc Drugs Ther. 1987. PMID: 3154314 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources